Evidence mapPaperPMID 42438017Full record

ReviewImmunological reviews2026

Atherosclerotic Cardiovascular Disease and Cancer.

Anaïs Amend, Hauke Horstmann, Kory J Lavine, Chiara Giannarelli, Kathryn J Moore

Abstract readReview
In one paragraph

Review in Immunological reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Anaïs AmendLeon H. Charney Division of Cardiology, Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA.ORCID https://orcid.org/0009-0006-2942-6066
Hauke HorstmannLeon H. Charney Division of Cardiology, Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA.
Kory J LavineDivision of Cardiology, Center for Cardiovascular Research, Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA.
Chiara GiannarelliLeon H. Charney Division of Cardiology, Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA.
Kathryn J MooreLeon H. Charney Division of Cardiology, Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA.ORCID https://orcid.org/0000-0003-2505-2547

Funding

Specification and Function of Tissue Resident and Recruited Macrophages in Cardiac Remodeling and Heart FailureR35HL161185 · NHLBI · WASHINGTON UNIVERSITY · 2023 to 2025
$2.6M
Resolving Macrophage Inflammation in Atherosclerotic Plaques and Other Sites in Insulin ResistanceP01HL131481 · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2025 to 2025
$2.6M
The role of immune-responsive gene 1 and itaconate in atherosclerotic diseaseR01HL172365 · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2025 to 2025
$758k
Long noncoding RNA regulation of Atherosclerotic Cardiovascular DiseaseR01HL172335 · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2025 to 2025
$732k
Dissecting the role of CD8+ T cells in atherosclerosisR01HL153712 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Chiara Giannarelli · 2022 to 2022
$668k
American Heart Association 26POST1563188DFG HO 7496/1-2Fondation Leducq 20CVD02NIH HHS P01HL131481NIH HHS R01HL153712NIH HHS R01HL172335NIH HHS R01HL172365NIH HHS R35HL161185
6 · The paper itself

Abstract

Atherosclerotic cardiovascular disease (ASCVD) and cancer are increasingly recognized as interconnected diseases linked by shared immune mechanisms rather than merely overlapping risk factors. Common exposures such as smoking, obesity, diabetes, and dyslipidemia, together with aging and clonal hematopoiesis of indeterminate potential (CHIP), establish a chronic inflammatory milieu that drives both pathologies through coordinated reprogramming of myeloid and lymphoid compartments. Within this framework, a forward cardio-oncology axis is increasingly recognized, in which cancer therapies including chemotherapies, radiation, and immune checkpoint inhibitors induce cardiovascular injury, manifesting as cardiomyopathy, accelerated atherosclerosis, and immune-mediated myocarditis. Complementing this, a reverse axis has emerged in which cardiovascular injury states such as myocardial infarction, ischemia, and heart failure actively promote cancer initiation and progression through hematopoietic remodeling, extracellular vesicle-mediated communication, cardiac-derived factors, and immunosuppressive myeloid bias. At the tissue level, immune checkpoint pathways including PD-1, PD-L1, CTLA-4, LAG-3, and TIM-3 form spatially organized regulatory networks within atherosclerotic plaques. Their therapeutic perturbation restores T cell activity but may disrupt local immune homeostasis and promote plaque instability. In parallel, inflammatory cytokines such as IL-1β, IL-6, and TNF-α, often amplified by CHIP-associated clones, provide a mechanistic bridge linking atherogenesis with tumor immune evasion. Together, these observations support a unified view of ASCVD and cancer as immune-driven diseases connected by bidirectional axes of interaction. This review integrates emerging mechanistic and clinical evidence and outlines how immune-based stratification and targeted modulation of inflammation may enable more precise management of patients at the intersection of cardiovascular disease and cancer.

Indexed as

AtherosclerosisCardiovascular DiseasesNeoplasmsAnimalsCytokinesDisease SusceptibilityHumansCytokinesatherosclerosiscardio‐oncologyclonal hematopoiesisextracellular vesiclesimmune checkpointsreverse cardio‐oncologytrained immunity

Identifiers

PMID42438017
PMCPMC13358037

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.